Back to top

gene-editing: Archive

Kevin Cook

Bull of the Day: NVIDIA (NVDA)

Owner of GPU architecture market accelerates "AI for everyone" with massive growth for years to come

NVDANegative Net Change CDNSPositive Net Change

Zacks Equity Research

Repare Therapeutics (RPTX) Rises 34% in a Week: Here's Why

Repare Therapeutics (RPTX) rises 34% in a week after announcing plans to begin clinal-stage development of two additional candidates, RP-1664 and RP-3467, in 2024 in several solid tumor indications.

LGNDNegative Net Change AGENPositive Net Change ACADPositive Net Change RPTXPositive Net Change

Zacks Equity Research

CRISPR (CRSP) to Report Q3 Earnings: What's in the Cards?

Devoid of marketed drugs, investors will focus on CRISPR Therapeutics' (CRSP) pipeline, specifically regulatory updates on lead candidate exa-cel.

GSKPositive Net Change BIIBPositive Net Change VRTXPositive Net Change CRSPPositive Net Change

Zacks Equity Research

BEAM Focuses on Developing Gene Drug for Growth

While BEAM's pipeline candidates are in early-stage clinical studies, their development is progressing well. Collaborations are a primary source of revenues in the absence of a marketed product.

PFEPositive Net Change VRTXPositive Net Change BEAMPositive Net Change CRSPPositive Net Change

Zacks Equity Research

QIAGEN (QGEN) Broadens QuantiFERON Line With EBV RUO Assay

QIAGEN (QGEN) notes that T-cells are vital in combatting viral infections and the QuantiFERON-EBV RUO assay focuses on measuring the T-cell response to EBV.

ALGNNegative Net Change HAEPositive Net Change QGENPositive Net Change QTRXPositive Net Change